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cells as shown for lymphoid cells before
(Truman et al., 1994).
Our results show an unexpected
MHCII overexpressing phenotype of
NF1-deficient SCs anticipating further
in depth analysis as it has several
potential important implications. The
phenotype may have a role in the
pathogenesis of neurofibroma through
tumor and immune cell interactions. It
would be interesting to search for
tumor-associated antigens which may
be presented on neurofibroma cells
and could serve as therapeutic targets.
HLA-DR expression itself which induces
pro-apoptotic and anti-proliferative sig-
nals after ligation may be useful for
therapeutic intervention. Given the
abundance of MHCII expression in neu-
rofibromin-deficient SCs targeting of
these tumorigenic cells via cytotoxin-
conjugated antibodies is also an option
for future therapeutic strategies. Further-
more, it will be interesting to evaluate
the potential benefit of a combinatorial
approach of anti-HLA-DR antibodies
with other compounds that have been
shown to be pro-apoptotic and anti-
proliferative in NF1-deficient cells such
as MEK inhibitors (See et al., 2012). In
any case mouse models will be
necessary to further investigate this
unusual phenotype.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by Deutsche Krebshilfe
(grant 105717) and BMBF (grant 01GM0841).
David E. Reuss1,2, Jana Mucha1,
Nikola Holtkamp3,11, Ute Mu¨ller4,
Hans-Peter Berlien4, Victor-Felix
Mautner5, Volker Ehemann6,
Michael Platten7,8, Klaus Scheffzek9,10
and Andreas von Deimling1,2
1CCU Neuropathology German Cancer
Research Center (DKFZ), Heidelberg, Germany;
2Institute of Pathology, Department
Neuropathology, University of Heidelberg,
Heidelberg, Germany; 3Department of
Neuropathology, Charite´-Universita¨tsmedizin
Berlin, Berlin, Germany; 4Department
Lasermedizin, Evangelische Elisabeth Klinik,
Berlin, Germany; 5Department of Neurology,
University Hospital Hamburg-Eppendorf,
Hamburg, Germany; 6Institute of Pathology,
University Hospital Heidelberg, Heidelberg,
Germany; 7Department of Neurooncology,
Neurology Clinic and National Center for
Tumor Diseases University Hospital of
Heidelberg, Heidelberg, Germany;
8Experimental Neuroimmunology Unit,
German Cancer Research Center (DKFZ),
Heidelberg, Germany; 9Structural and
Computational Biology and Developmental
Biology Units, European Laboratory of
Molecular Biology (EMBL), Heidelberg,
Germany and 10Division of Biological
Chemistry, Biocenter, Innsbruck Medical
University, Innsbruck, Austria
E-mail: Klaus.Scheffzek@i-med.ac.at or
andreas.vondeimling@med.uni-heidelberg.de
11Current address: Nikola Holtkamp,
Brandenburg Centrum fu¨r Regenerative
Therapien (BCRT), Charite´-Universita¨tsmedizin
Berlin, Berlin, Germany
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Altomonte M, Pucillo C, Maio M (1999) The
overlooked "nonclassical" functions of major
histocompatibility complex (MHC) class II
antigens in immune and nonimmune cells.
J Cell Physiol 179:251–6
Campoli M, Ferrone S (2008) HLA antigen changes
in malignant cells: epigenetic mechanisms and
biologic significance. Oncogene 27:5869–85
Krawczyk M, Reith W (2006) Regulation of MHC
class II expression, a unique regulatory system
identified by the study of a primary immuno-
deficiency disease. Tissue antigen 67:183–97
Nagy ZA, Hubner B, Lohning C et al. (2002) Fully
human, HLA-DR-specific monoclonal antibo-
dies efficiently induce programmed death of
malignant lymphoid cells. Nat Med 8:801–7
Riccardi VM (1999) Neurofibromatosis: Phenotype,
Natural History and Pathogenesis. The John
Hopkins University Press: Baltimore
See WL, Tan IL, Mukherjee J et al. (2012) Sensi-
tivity of glioblastomas to clinically available
MEK inhibitors is defined by neurofibromin 1
deficiency. Cancer Res 72:3350–9
Serra E, Rosenbaum T, Winner U et al. (2000)
Schwann cells harbor the somatic NF1 muta-
tion in neurofibromas: evidence of two differ-
ent Schwann cell subpopulations. Hum Mol
Genet 9:3055–64
Tran CT, Wolz P, Egensperger R et al. (1998)
Differential expression of MHC class II mole-
cules by microglia and neoplastic astroglia:
relevance for the escape of astrocytoma cells
from immune surveillance. Neuropathol Appl
Neurobiol 24:293–301
Truman JP, Ericson ML, Choqueux-Seebold CJ
et al. (1994) Lymphocyte programmed cell
death is mediated via HLA class II DR. Int
Immunol 6:887–96
Viskochil D, Buchberg AM, Xu G et al. (1990)
Deletions and a translocation interrupt a
cloned gene at the neurofibromatosis type 1
locus. Cell 62:187–92
Wallace MR, Marchuk DA, Andersen LB et al.
(1990) Type 1 neurofibromatosis gene: identi-
fication of a large transcript disrupted in three
NF1 patients. Science 249:181–6
Zhu Y, Ghosh P, Charnay P et al. (2002) Neuro-
fibromas in NF1: Schwann cell origin and role
of tumor environment. Science 296:920–2
MCP-1 as an Effector of IL-31 Signaling in Familial
Primary Cutaneous Amyloidosis
Journal of Investigative Dermatology (2013) 133, 1375–1378; doi:10.1038/jid.2012.484; published online 10 January 2013
TO THE EDITOR
Primary cutaneous amyloidosis (PCA) is
an itchy skin disorder that is relatively
common in South America and
Southeast Asia (Ollague et al., 1990;
Tan, 1990). The disease is characterized
histologically by focal deposition of
amyloid in the dermal papillae of
lesional skin, but its etiology is un-
known. Although not life-threatening,
the disease affects the patients’ quality
of life severely from uncomfortable
conditions, i.e., itching and undesir-
able appearance. Most PCA cases are
sporadic, but a genetic factor has been
reported to be responsible for the
Abbreviations: IL-31RA, IL-31 receptor A; MCP-1, monocyte chemotactic protein-1; PCA, primary
cutaneous amyloidosis
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disease pathogenesis. Indeed, a signifi-
cant number of PCA patients in Taiwan
have a family history (familial PCA,
FPCA). Our analysis and that of
others of PCA with a positive family
history identified missense mutations in
the OSMRb and IL-31 receptor A
(IL-31RA) genes from families in
Brazil, Britain, South Africa, and Tai-
wan (Arita et al., 2008; Lin et al., 2010).
Products of these genes, OSMRb and IL-
31RA, are the subunits of the transmem-
brane receptor for IL-31, a recently dis-
covered pruritogenic cytokine (Zhang
et al., 2008). All the FPCA mutations
found in either subunit are located in
the membrane proximal fibronectin III
domain that has an important role in the
downstream signaling (Pflanz et al.,
2001). Furthermore, only one mutation
was found for each case, and the
mutation in OSMRb and in IL-31RA
was mutually exclusive. These facts
suggested a link between the IL-31
signaling and pathogenesis of PCA,
and that each mutation may be
functionally equivalent.
HaCaT, a human keratinocyte cell
line, contains a negligible amount of
IL-31RA (Cornelissen et al. (2012) and
Supplementary Figure S1 online). There-
fore, we generated stably transfected
HaCaT cell clones for the current inves-
tigation. Here we designated these cell
clones CN (for vector control), WT (for
wild-type IL-31RA), and MT (for mutant
IL-31RA-S521F), respectively.
IL-31 can induce the secretion of
proinflammatory cytokines and chemo-
kines (Yagi et al., 2007; Cornelissen
et al., 2012). Chemokine/cytokine
protein arrays revealed a significant
difference between WT and MT
cells in the expression profile of mono-
cyte chemotactic protein-1 (MCP-1)
(Figure 1a). This difference was vali-
dated by ELISA, which showed a strong
induction of MCP-1 by IL-31 treatment
from WT but not from MT cells
(Figure 1b). The difference is not due
to clonal variation, as other clones also
showed the same result (Supplementary
Figure S2a online). Furthermore, a simi-
lar result was obtained from transient
transfection system (Supplementary
Figure S2b online). Quantitative PCR
analysis showed a very low and IL-31-
insensitive MCP-1 transcription in MT
cells (Figure 1c). MCP-1 can attract
immune cells such as monocytes,
which would differentiate to macro-
phages at the sites of injury or inflam-
mation. Chemotaxis assay revealed that
the keratinocytes harboring the IL-31RA-
S521F mutant have an impaired IL-31-
induced chemotactic activity toward
monocytes (Figure 1d). As MCP-1 is
the major IL-31-induced chemoattrac-
tant from HaCaT cells (Supplementary
Figure S3 online), the reduced
chemotactic activity of MT cells is due
to the low MCP-1.
To investigate the status of MCP-1 in
PCA tissues, an MCP-1-specific anti-
body was used for immunofluorescence
microscopy with formalin-fixed skin
samples of the two major types of PCA
(7 cases of macular amyloidosis and 8
cases of lichen amyloidosis) (Figure 2a
and Supplementary Table S1 online).
Except for one case with severe lichen
reaction, all others were weakly stained
by the antibody. By contrast, two pro-
liferative and inflammatory conditions,
psoriasis and pemphigus, showed strong
staining in the suprabasal layers of the
epidermis. In addition, variable levels
of MCP-1 protein expression were
detected for eczema, a well-known
itching disorder (data not shown). Thus,
consistent with the in vitro findings,
MCP-1 level in PCA was not elevated
in vivo, despite the fact that the patients
suffered from severe pruritus. Written,
informed consent was obtained from
each participant, under protocols
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Figure 1. Impaired monocyte chemotactic protein-1 (MCP-1) expression in HaCaT cells with the familial
primary cutaneous amyloidosis (FPCA) IL-31 receptor A mutant (MT) (IL-31RA-S521F). (a) Protein array
analysis of HaCaT cells. Cells (wild type (WT) and MT) were serum-starved before being treated with
50 ng ml1 IL-31 for the time periods indicated. Conditioned medium was applied to a cytokine/
chemokine protein array. Although IL-8 (green) and regulated and normal T cell expressed and secreted
(RANTES) (red) remained relatively constant throughout the time course, MCP-1 (blue) was induced by
IL-31 treatment. The MCP-1 level in MT cells was much lower and insensitive to IL-31. (b) Validation of the
differential MCP-1 expression. Cells were treated with IL-31 for the indicated time periods. Conditioned
medium was applied to ELISA for the quantitation of MCP-1. Each point was triplicated, and mean±SD is
shown. (c) Diminished MCP-1 transcription in MT cells. WT and MT cells were treated with IL-31. The
level of MCP-1 transcript was measured by quantitative RT–PCR using actin as an internal standard. The
relative level of transcripts was normalized with the value of unstimulated WT cells. (d) Failure of
conditioned medium from MT cells to attract monocytes. THP-1 cells were seeded on the Millicell cell
culture insert. Conditioned medium from HaCaT cells treated (or untreated) with IL-31 was added to the
lower chamber. For the controls, medium with (positive) or without (negative) MCP-1 was used instead of
the conditioned medium. THP-1 cells that migrated through the membrane within 3 hours were counted.
Means±SD from triplicated experiments are shown. CN, vector control.
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approved by the research ethics board
of the hospital that follows Declaration
of Helsinki Principles.
Besides cytokine/chemokine regula-
tion, IL-31 can regulate cell growth
(Chattopadhyay et al., 2007). IL-31
inhibits the growth of WT cells. The IL-
31RA mutation did not alter this effect
of IL-31 signaling, as MT cell
growth was equally inhibited by IL-31
(Supplementary Figure S4a online). Con-
sistently, we did not observe a
significant difference in the status of cell
cycle regulators between WT and MT
cells (Supplementary Figure S4a online).
Other cytokines such as IL-20 and
IL-24 are also regulated by IL-31
(Cornelissen et al., 2012). The IL-31RA
mutation, however, showed no signifi-
cant effect on the regulation of these
cytokines (Supplementary Figure S4b
online).
We observed that IL-31-stimulated
signal transducer and activator of tran-
scription 3 (STAT3) activation was sig-
nificantly lower in MT cells compared
with that in WT cells (Supplementary
Figure S5a online). A similar phenom-
enon was reported in primary keratino-
cytes harboring an FPCA-derived
mutation in the OSMRb subunit
(Arita et al., 2008). STAT3 is an
important factor in MCP-1 regulation
in tumor cells, as well as in keratino-
cytes (Burysek et al. (2002), Jougasaki
et al. (2010), and Supplementary Figure
S5b online). Therefore, it is possible that
the impaired IL-31-induced production
of MCP-1 in MT cells is, at least in part,
attributed to the much-reduced STAT3
activation in IL-31 signaling. As many
factors are involved in MCP-1 regula-
tion, we could not exclude the possibi-
lity that molecular effectors other than
STAT3 in the signaling pathway
also contribute to the impaired MCP-1
production in MT cells.
Amyloidosis is a result of deposition
of insoluble misfolded proteins and cel-
lular debris on tissues (Merlini and
Bellotti, 2003). The innate immune
system keeps such cellular debris from
accumulating. Deficiency of this
scavenger function has been observed
in Alzheimer’s disease (AD), a disease
that is also characterized by amyloidosis
(Fiala et al., 2005; Cashman et al.,
2008). Although the pathogenesis of
PCA and AD is different, it is possible
that failure of cellular debris clearance
from the lesional tissues by the innate
immunity may be a common
phenomenon to the two conditions.
Our observations suggest that the
amyloid clearance of keratinocytes
is compromised because of limited
recruitment of immune cells to the
lesional sites (Figure 2b). It is reasonable
to speculate whether genetic poly-
morphisms of MCP-1 (Rovin et al.,
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Inflammatory
skin disorder
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Primary
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Psoriasis vulgaris
Macular amyloidosis
Normal FPCA
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Keratinocytes with mutant receptor
IL-31
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0.1 mm
Figure 2. Low monocyte chemotactic protein-1 (MCP-1) expression in primary cutaneous amyloidosis
(PCA) skin specimens. (a) MCP-1 expression level in various skin conditions was analyzed by
immunofluorescence microscopy. Low immunoreactive intensity in normal skin specimens obtained from
patients with epidermal cyst. Skin specimens of inflammatory skin disorders, bullous pemphigoid, and
psoriasis vulgaris had high MCP-1 immunoreactivity. By contrast, marginal MCP-1 expression was
observed in PCA skin specimens obtained from patients with PCA, lichen amyloidosis, or macular
amyloidosis. Representative staining of each case with the same magnification is shown. Bar¼0.1mm is
shown in the middle left panel. The summary of the result is shown in Supplementary Table S1 online.
(b) Hypothetical model for the familial PCA (FPCA) pathogenesis. (Left) Normal keratinocytes can recruit
innate immune cells that clear the cellular debris. (Right) FPCA keratinocytes fail to attract innate immune
cells because of compromised MCP-1 production through IL-31 signaling. As a result, cellular debris
cannot be cleared properly, leading to its accumulation and ultimately to amyloidosis.
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1999) or the components of the IL-31
receptor might be involved in the
pathogenesis of sporadic PCA.
Although additional work is required to
translate our current finding to disease
management, modulation of MCP-1
level and function, through IL-31-
dependent and -independent pathways,
may offer a new approach for
therapeutic development for FPCA.
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TO THE EDITOR
Metastatic melanoma patients harboring
a BRAF gene mutation on codon 600
can be treated with targeted therapies
(Flaherty, 2012). Depending on the
content of tumor cells and on the
analytical sensitivity, BRAF mutations
are found in 50–70% of metastatic
melanoma patients (Davies et al.,
2002). Around 80% display a valine-
to-glutamic acid substitution (V600E)
and B16% harbor a valine-to-
lysine substitution (V600K) causing
constitutive kinase activation (Wan
et al., 2004; Rubinstein et al., 2010).
BRAFV600E mutation analysis is currently
performed in daily clinical practice on
tissue samples using various molecular
biology technologies. Moreover, the
detection of the BRAFV600E mutation in
blood samples from melanoma patients
in the context of translational research
and clinical trials has been des-
cribed (Board et al., 2009; Sakaizawa
et al., 2012). Metastatic dissemination
Abbreviations: CMCs, circulating melanoma tumor cells; CTCs, circulating tumor cells; ICC,
immunocytochemistry; IHC, immunohistochemistry; ISET, isolation by size of epithelial tumor cells
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